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Antonucci et al. demonstrate that a primary increase in superoxide selectively 
within the mitochondria directly impacts on mitochondrial and cell function. Moreover, 
a slight increase in mitochondrial ROS is protective against cardiac ischaemia-
reperfusion injury despite negative effects at higher concentrations. 
1 Abstract 
Reactive oxygen species (ROS) have an equivocal role in myocardial ischaemia 
reperfusion injury. Within the cardiomyocyte, mitochondria are both a major source 
and target of ROS. We evaluate the effects of a selective, dose-dependent increase 
in mitochondrial ROS levels on cardiac physiology using the mitochondria-targeted 
redox cycler MitoParaquat (MitoPQ). Low levels of ROS decrease the susceptibility of 
neonatal rat ventricular myocytes (NRVMs) to anoxia/reoxygenation injury and also 
cause profound protection in an in vivo mouse model of ischaemia/reperfusion. 
However higher doses of MitoPQ resulted in a progressive alteration of intracellular 
[Ca2+] homeostasis and mitochondrial function in vitro, leading to dysfunction and 
death at high doses. Our data show that a primary increase in mitochondrial ROS can 
alter cellular function, and support a hormetic model in which low levels of ROS are 
cardioprotective while higher levels of ROS are cardiotoxic.  
  
2 Introduction 
Ischaemia/reperfusion (I/R) injury occurs when the blood supply to a region of 
tissue is disrupted and later restored. Key to the development of the pathology is a 
lack of oxygen for oxidative phosphorylation within mitochondria. This results in the 
arrest of forward electron flow in the respiratory chain (Di Lisa et al., 1998) due to the 
lack of oxygen to act as the terminal electron acceptor. Consequently, succinate is 
accumulated during ischaemia by the reduction of fumarate at mitochondrial complex 
II (Chouchani et al., 2014), or from anaplerotic supply of glutamate to the tricarboxylic 
acid cycle leading to succinate that cannot be oxidized due to the reduced Coenzyme 
Q pool (Zhang et al., 2018). At reperfusion, the re-introduction of oxygen leads to 
sudden changes in myocardial viability, mediated by a burst of ROS production within 
the mitochondria. While a number of sources of ROS have been proposed to be 
responsible, recently it has been shown that the succinate pool accumulated during 
ischaemia is rapidly oxidized upon reperfusion, driving ROS production from complex 
I through reverse electron transport (Chouchani et al., 2014). The sustained opening 
of the mitochondrial permeability transition pore (mPTP), a key arbiter of cell fate, also 
results in significant ROS production. As ROS are among the factors contributing to 
prolonged mPTP opening there is a positive feedback loop of ROS-induced ROS 
release (Zorov et al., 2014) through which ROS generation results in sustained 
mitochondrial dysfunction and eventually cell death (Di Lisa et al., 2011). 
 However, aside from their role in driving mPTP-mediated cell damage, 
mitochondrial ROS production also impacts positively on several aspects of 
myocardial I/R injury. Mitochondrial ROS play crucial roles in signalling processes both 
within mitochondria and in their interplay with other cellular sites (Janssen-Heininger 
et al., 2008). Indeed, the protective mechanism underlying ischaemic preconditioning 
(IPC) appears to involve generation of low levels of ROS (Collins et al., 2012; Robin 
et al., 2007; Sena and Chandel, 2012). This has been demonstrated by showing that 
the protective effects of an IPC protocol may be abrogated by antioxidants (Eguchi et 
al., 2003; Hao et al., 2016; Horwitz et al., 1994; Klein et al., 1989; Mickle et al., 1989; 
Nishinaka et al., 1992; Peng et al., 2011), or replicated by the addition of exogenous 
oxidants in a pre- or post-conditioning like manner (Hegstad et al., 1997; Tritto et al., 
1997; Ytrehus et al., 1995). Indeed, it has been demonstrated that the acute treatment 
with H2O2 in a model of Langerdorff perfused hearts elicits cardioprotection in a 
preconditioning-like manner depending of its concentration (Valen et al., 1998; 
Yaguchi et al., 2003). These findings that ROS can be either cardiotoxic or 
cardioprotective, depending on the context, may help explain why the use of general 
ROS scavengers has yielded mixed results. For example there are also studies in 
experimental models that report no effect of antioxidants upon I/R injury (Bellows et 
al., 1995; Gao et al., 2002; Meyer et al., 2013; Tripathi and Hegde, 1998). In the clinic, 
large scale trials with antioxidants have produced equivocal effects upon 
cardiovascular health outcomes (Fortmann et al., 2013; Ye et al., 2013). These 
findings are also consistent with the growing appreciation for the differential effects of 
“good” and “bad” ROS (Ristow, 2014; Schwartz and Sack, 2008; Yun and Finkel, 
2014), by which ROS can either contribute to cell death, or at low levels activate 
cardioprotective mechanisms: a concept referred to as ‘hormesis’. 
The context in which ROS might lead to these opposing consequences will arise 
due to differential effects of ROS production in three primary dimensions: in 
magnitude, in timing, and in spatial distribution. A better understanding of, and control 
of these dimensions over ROS production may provide mechanistic insights as to how 
ROS can have different effects. Here, we address this point by exploring the role of 
ROS generated within mitochondria at different concentrations, and characterize the 
processes linking changes in mitochondrial ROS levels to cardiac pathophysiology 
with focus on cardiac I/R injury. To investigate the consequences of a primary increase 
in ROS specifically within the mitochondrial compartment, we used the mitochondria-
targeted compound MitoParaquat (MitoPQ) (Robb et al., 2015). MitoPQ was designed 
based upon the conjugation of a paraquat moiety (1,1’-dimethyl-4,4’-bipyridinium 
dichloride) (Hassan, 1984) with the mitochondria targeting triphenylphosphonium 
group. At the flavin site of complex I in the electron transport chain, MitoPQ accepts 
an electron to generate a radical monocation that reacts rapidly with oxygen to 
specifically generate superoxide, which is the proximal ROS species produced 
endogenously (Birrell et al., 2011).  
In this work we demonstrate that a selective primary increase in mitochondrial 
ROS is a causal factor in changes of mitochondrial and cell function, and show that 
low levels of mitochondrial ROS are protective against ischaemic injury both in vitro 
and in vivo, while higher levels are damaging. 
3 Results 
3.1 MitoPQ induces a primary increase in mitochondrial ROS levels 
in a dose-dependent manner 
To investigate the effects of mitochondrial ROS production by MitoPQ in 
cardiomyocytes, neonatal rat ventricular myocytes (NRVMs) were treated for 2 h with 
different doses of MitoPQ. High levels of ROS were assessed with a reduced form of 
MitoTracker Red (MTR) that fluoresces only following oxidation. However, MTR 
presents some limitations due to its relative lack of sensitivity and specificity, that its 
accumulation depends on cell and mitochondrial membrane potential (ΔΨm), and 
these can be affected by different treatments independently of ROS formation. 
Therefore, to detect low levels of ROS we used MitoHyPer, a genetically encoded 
sensor that is highly specific and sensitive for sub-micromolar concentrations of 
mitochondrial H2O2 (Belousov et al., 2006).  
MitoPQ caused a significant increase in mitochondrial ROS levels in a dose-
dependent manner that was not observed when cells were pre-treated with the 
antioxidant N-(2-Mercaptopropionyl)glycine (MPG) (FIGURE 1A-C). Cells treated with 
a MitoPQ control compound (Supplementary FIGURE 1) that is structurally similar to 
MitoPQ but which does not undergo redox cycling did not show an increase in 
mitochondrial ROS levels (FIGURE 1B-D, Supplementary FIGURE 2A-B). Moreover, 
cells treated with non-mitochondrial paraquat (PQ) did not show an increase in 
mitochondrial ROS levels (Supplementary FIGURE 2C), in line with previous reports 
(Robb et al., 2015). 
Taken together, these data confirm that MitoPQ produces ROS within 
mitochondria in a dose-dependent manner. 
3.2 A primary increase in mitochondrial ROS levels affects 
mitochondrial function in a dose-dependent manner 
An increase in mitochondrial ROS production has been reported to induce a 
decrease in ΔΨm that is associated with mPTP opening (Fauconnier et al., 2007; 
Kokoszka et al., 2001). To investigate whether MitoPQ-induced ROS affect 
mitochondrial function, we monitored ΔΨm using tetramethylrhodamine fluorescence. 
NRVMs treated with different doses of MitoPQ displayed a dose-dependent decrease 
in ΔΨm (FIGURE 2A). Notably, although promoting H2O2 formation (FIGURE 1C), 
0.01 µM MitoPQ did not affect ΔΨm. However, a defective electron transport chain 
may not lead to a detectable decrease in ΔΨm, since in isolated cells the proton 
gradient can be maintained by the reverse activity of FOF1 ATP synthase (Di Lisa et 
al., 1995). This compensatory process was abolished by the presence of the FOF1 
ATPase inhibitor oligomycin in all the experiments. The lack of ΔΨm variations at low 
MitoPQ doses suggests that mild ROS formation is unlikely to alter electron transport 
chain function. Taken together, these results show that a primary increase in 
mitochondrial ROS formation decreases ΔΨm in a dose-dependent manner, but that 
this does not occur at low ROS levels.  
Analysing the causal relationship between mPTP, ROS formation and ΔΨm is 
complicated by the fact that mPTP opening is both a cause and a consequence of 
ΔΨm loss and mitochondrial ROS generation (Bernardi, 1992; Bernardi et al., 2006; 
Petronilli et al., 1993). Hence, we used MitoPQ to investigate the effects of a primary 
increase in mitochondrial ROS levels on mPTP induction assessed by monitoring 
calcein fluorescence (Huser et al., 1998; Petronilli et al., 1999). NRVMs were pre-
treated with or without cyclosporine A (CsA), a desensitizer of the mPTP. Since CsA 
is also an inhibitor of the multidrug resistance P-glycoproteins (MDR), which may alter 
MitoPQ distribution, cells were pre-treated also with cyclosporine H which inhibits the 
MDRs but does not affect mPTP opening (Dietel et al., 1994). Treatment with 0.5 µM 
MitoPQ induced a rapid decrease in calcein fluorescence (~30%) that was prevented 
by CsA. MitoPQ-induced mPTP opening was dependent on ROS formation since it 
was abrogated by MPG. Notably, MPG did not display any effect when mPTP opening 
was induced by calcimycin (FIGURE 2B). Taken together, these results indicate that 
ROS induced by 0.5 µM MitoPQ lead to mPTP opening in NRVMs.  
3.3 A primary increase in mitochondrial ROS levels affects cell 
function and viability 
We hypothesized that mitochondrial ROS would affect cellular sites and functions 
outside the mitochondria. In particular, our attention was focused on [Ca2+]I 
homeostasis due to its central role in cardiac physiology (Eisner, 2014; Fearnley et al., 
2011). Treatment with 0.01 μM MitoPQ caused a significant increase in both amplitude 
(FIGURE 3B) and response of the sarcoplasmic reticulum to caffeine (FIGURE 3E), 
without affecting the oscillatory pattern or the frequency of the Ca2+ transients 
(FIGURE 3A-D). In contrast, doses of MitoPQ > 0.01 μM induced dose-dependent 
alterations in all the oscillatory parameters. Notably, increasing MitoPQ concentration 
to 0.1 µM disrupted [Ca2+]I homeostasis, causing the cells to become unexcitable 
(FIGURE 3). Overall, these findings demonstrate that ROS produced within 
mitochondria alter [Ca2+]I homeostasis within the cytosol and endoplasmic reticulum 
with different amounts of ROS causing different effects. 
Since oxidative stress associated with mitochondrial dysfunction is known to 
decrease cell viability (Carpi et al., 2009; Yancey et al., 2015), we investigated whether 
MitoPQ-induced oxidative stress could lead to cell death in NRVMs. The loss of cell 
viability was measured as lactate dehydrogenase (LDH) release in NRVMs treated for 
24 h with increasing doses of MitoPQ. MitoPQ doses ≥ 0.5 µM significantly increased 
cell death (~30%) which could be abrogated by the addition of the free radical 
scavenger MPG (FIGURE 3F). Notably, 0.1 µM MitoPQ did not significantly alter cell 
viability despite promoting ROS formation, mitochondrial dysfunction and [Ca2+]I 
dyshomeostasis without mPTP opening. Therefore, we hypothesized that the 
decreased cell viability at high concentrations of MitoPQ was related to mPTP opening 
(Bernardi et al., 2001; Di Lisa et al., 2009). This was confirmed by CsA treatment which 
prevented cell death induced by MitoPQ at doses ≥ 0.5 μM (FIGURE 3G).  
3.4 Low levels of MitoPQ-induced ROS reduce cell death following 
anoxia/reoxygenation 
We demonstrated that low doses of MitoPQ (0.01 µM) elevated ROS but did not 
alter mitochondrial function, [Ca2+]I homeostasis and cell viability. Since an increase 
in mitochondrial ROS levels have been proposed to be involved in IPC (Di Lisa et al., 
2011; Halestrap, 2010; Hausenloy et al., 2016; Murphy and Steenbergen, 2007), we 
hypothesized that a primary increase in non-toxic mitochondrial ROS levels by MitoPQ 
might enhance tolerance to post-anoxic injury. To assess this, we evaluated whether 
the low dose of MitoPQ could mimic the protection elicited by IPC against 
anoxia/reoxygenation injury. Cells pre-treated with 0.01 µM MitoPQ, with or without 
the antioxidant MPG, were exposed to 12 h of anoxia followed by 1 h of reoxygenation. 
MitoPQ treatment significantly decreased cell death both at the end of anoxia and 
following reoxygenation. The cardioprotective effect of MitoPQ was lost in cells treated 
with MPG (FIGURE 4A). In addition, an identical concentration of the MitoPQ control 
compound did not induce any protection. Notably, the reliability of the protocol has 
been assessed by the protective effect elicited by CsA in NRVMs exposed to 
anoxia/reoxygenation (Supplementary FIGURE 2D). These data indicate that the 
increase in cell viability was due to MitoPQ-induced ROS.  
3.5 MitoPQ reduces infarct size in an in vivo model of 
ischaemia/reperfusion injury 
Finally, we utilized an in vivo surgical model of acute myocardial I/R injury in the 
mouse to determine the effect of a primary increase of ROS produced by MitoPQ upon 
infarct size. A bolus of MitoPQ was given by i.v. injection 15 minutes prior to the onset 
of cardiac ischaemia produced by occlusion of the left anterior descending coronary 
artery. This was followed by 2 hours reperfusion. Elevating mitochondrial ROS by 
intermediate doses of MitoPQ (i.e. 0.01 – 0.1 nmol) significantly reduced infarct size 
compared to both DMSO-only control or MitoPQ control compound (FIGURE 4B-C-
D). However, at both lower or higher doses of MitoPQ no protection was observed, 
and a dose of 5 nmol MitoPQ was fatal. This shows that low levels of mitochondrial 
ROS can be cardioprotective during I/R injury in vivo, while higher levels of ROS cause 
damage. 
Considering the changes caused in cellular calcium dynamics observed following 
treatment of NRVMs with MitoPQ, we evaluated its effects on haemodynamics in vivo 
using dynamic measurements of left ventricular pressure and volume. However no 
significant difference was observed between animals injected with the most 
cardioprotective dose of MitoPQ compared with hearts treated with vehicle only 
(Supplementary TABLE 1).  
4 Discussion 
This study demonstrates that the primary formation of mitochondrial ROS exerts 
differential effects upon the heart during acute myocardial I/R injury, with 
cardioprotection conferred by a narrow intermediate dose range whilst no reduction in 
infarct size was observed at either higher or lower doses. This primary increase in 
mitochondrial ROS is also shown to have effects on mitochondrial function, [Ca2+]I 
homeostasis and cell viability in a dose-dependent manner.  
Until this point, studies assessing the effects of the alteration of intracellular ROS 
levels have necessarily used crude approaches to modulate ROS, which poorly mimic 
the (patho)physiological generation of ROS. For example, the application of 
exogenous hydrogen peroxide or exposure to a purine/xanthine oxygen radical 
generating system both require the ROS to diffuse into the cell, rather than being 
generated selectively within cell compartments such as the mitochondria. These 
limitations have been addressed by using MitoPQ (Robb et al., 2015). MitoPQ’s 
mitochondrial accumulation allows it to be used at concentrations several hundred-
fold lower than untargeted paraquat and importantly this selective accumulation 
means that ROS are only produced within mitochondria. The direct generation of 
superoxide rather than downstream ROS also mirrors its production in 
(patho)physiology as the proximal species (Murphy, 2009). This has been validated to 
occur without detectable ROS production in the cytosol (considered for publication 
elsewhere). The dose-dependent effect of MitoPQ on mitochondrial ROS production 
therefore allows the generation of exogenous ROS in a highly specific manner. Based 
on these features, MitoPQ represents a unique tool to investigate and characterize the 
effects of a precise increase in mitochondrial ROS formation on cell physiology, both 
in vitro and in vivo. 
There is a growing body of evidence indicating that mitochondrial ROS exert 
differential effects depending on their dose, which has been called a “hormetic” dose-
response curve (Ristow and Schmeisser, 2014). In our experiments, high levels of 
ROS induced by MitoPQ (i.e. 0.5 – 1 µM) lead to mitochondrial dysfunction, mPTP 
opening and eventually cell death. Such detrimental effects of ROS in I/R injury 
through the opening of the mPTP have been well described (Di Lisa et al., 2011). 
Intermediate doses of ROS (i.e. 0.1 µM MitoPQ) did not affect cell viability but did 
cause an alteration in the amplitude of calcium transients and their response to 
caffeine. At low doses (i.e. 0.01 µM), ROS generation induced by MitoPQ slightly 
modulates [Ca2+]I homeostasis without affecting either mitochondrial function or cell 
viability. Importantly, isolated cardiomyocytes pre-treated with low doses of MitoPQ 
and then exposed to anoxic injury displayed increased cell viability. This in vitro result 
was paralleled by the reduction of infarct size obtained in vivo in mice pre-treated with 
doses of MitoPQ ranging from 0.01 nmol to 1 nmol per mouse. Therefore, 
mitochondrial-derived ROS elicit a wide range of responses which are dependent on 
their dose, ranging from the disruption of ΔΨm and mPTP opening at high doses of 
MitoPQ to the reduction of cell death and infarct size at low doses of MitoPQ in a 
preconditioning-like manner. The absence of protective effects observed with both low 
and high doses of MitoPQ in vivo (i.e. 0.001 – 1 nmol) highlights the hormetic effect 
elicited by intermediate levels of ROS. Moreover, higher doses of MitoPQ (i.e. 2.5 – 5 
– 10 nmol) displayed to be lethal in vivo. The concept of hormesis helps to rationalize 
the paradoxical effect of both injury and protection elicited by ROS described in 
literature, as well as the failure of clinical trials using general administration of 
antioxidants. 
The data presented also show that a number of ROS-related events spread from 
mitochondria to the cytosolic compartment. As the source of ROS generation in our 
experiments is within mitochondria, we provide the first direct evidence that a primary 
increase in mitochondrial ROS formation can induce cardioprotection both in vitro and 
in vivo via changes in mitochondrial and cellular function. The known interplay 
between ROS and [Ca2+]I homeostasis is of central relevance to the cardiomyocyte 
and has specifically been implicated in several disease states (Carvajal et al., 2014), 
but it has been difficult to determine the primacy of one factor upon the other. Taken 
together, our findings show that a primary increase in mitochondrial ROS can impact 
on the cytosol, altering [Ca2+]I homeostasis and thereby whole cell function. 
It is worth noting that while we have determined the doses of MitoPQ associated 
with the various effects in mitochondria and in intact cells, the actual concentrations of 
ROS required for cardiomyocytes injury and protection remain to be established due 
to the technically challenging nature of their measurement, especially in vivo 
(Wardman, 2007). Moreover, since we have utilised healthy young male animals for 
our in vivo model it remains to be seen how comorbidities such as obesity, diabetes, 
aging and sex modulate the response to a given quantity of mitochondrial ROS, since 
for example the protective efficacy of IPC is lost in aged or diabetic hearts (Hausenloy 
et al., 2016).  
In conclusion, we have demonstrated that a primary increase in mitochondrial 
ROS exerts effects on both mitochondrial and cell function, which presents 
mitochondrial ROS as a cause rather than consequence of the functional change in 
cardiac (patho)physiology. Notably, the generation of exogenous ROS by MitoPQ 
within mitochondria is found to exert differential effects, with a hormetic dose response 
curve in which protection is observed only at an intermediate level of mitochondrial 
ROS, but not at either lower or higher levels.  
 
5 Methods 
5.1 Cell culture 
5.1.1 NRVMs 
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-3 day old 
Wistar rats as described previously (Kaludercic et al., 2014). Briefly, hearts were 
excised, cut into smaller pieces and left overnight at 4°C for digestion by 2.5% trypsin 
10X (Thermo Fisher Scientific) in HBSS (Sigma). The next day, tissues were incubated 
with 0.75 mg/ml collagenase type II (Thermo Fisher Scientific) in HBSS for 10 min (at 
2 min intervals) at 37°C and cells dissociated by pipetting. Following centrifugation at 
300 g for 7 min, cells were resuspended in MEM (Invitrogen) and pre-plated for 2 h to 
let cardiac fibroblasts attach to the plastic surface. Plates and coverslips were coated 
with a solution of 0.1% porcine gelatin (Sigma) and incubated at 37°C for 1 h. The 
non-adherent myocytes were plated in gelatin coated plates at variable density (at 
least 1x105 cells/ml) in MEM supplemented with 10% FBS (Thermo Fisher Scientific), 
1% penicillin/streptomycin (Thermo Fisher Scientific), 1% non-essential amino acids 
(Thermo Fisher Scientific), 1 mM 5-Bromo-2-Deoxyuridine (Sigma). Cells were 
maintained at 37°C in presence of 5% CO2. The medium was changed to MEM 
supplemented with 1% FBS, 1% penicillin/streptomycin and 1% non-essential amino 
acids after 24 h of plating.  
 To evoke a primary increase in mitochondrial ROS, NRVMs were treated in 
culture medium with different concentrations of MitoPQ (Robb et al., 2015), from 0.01 
to 1 µM for 2 h, unless specified in results. A MitoPQ control compound was also used 
that has a very similar structure to MitoPQ and similar levels of uptake into 
mitochondria, but which cannot generate ROS by redox cycling. MitoPQ redox cycles 
because it can receive an electron from the FMNH2 of complex I reducing the viologen 
dication to a radical cation, which then reduces oxygen to superoxide to regenerate 
MitoPQ (Supplemental FIGURE 1). MitoPQ control employs the twisted viologen unit 
described by (Andersson et al., 2009), in which two extra methyl groups disfavour the 
coplanarity of the two pyridine units required to stabilize a radical cation. We have 
previously reported its use (Fazakerley et al., 2018), but here give full details of its 
synthesis in two steps by double alkylation of 3’-dimethyl-4,4’-dipyridyl, prepared by 
the procedure of (Rebek et al., 1985) (Supplementary FIGURE 3). To scavenge ROS, 
cells were pre-treated with 500 µM MPG (Sigma) (Perrelli et al., 2011) for 30 min. To 
prevent mPTP opening, cells were pre-treated with 1 µM CsA (Sigma) (Di Lisa et al., 
2001) for 30 min.  
5.1.2 Transfection 
NRVMs were plated on six-well plates at a density of 3x105 cells/well and 
transfected with Lipofectamine 3000 reagent (Sigma). For each transfection, 2.5 µg of 
MitoHyPer (Evrogen) was diluted in 125 µl of Opti-MEM medium (Thermo Fisher 
Scientific) in presence of 5 µl of P3000™ reagent (Life Technologies) and later 
combined with 4 µl of Lipofectamine™ 3000 (Life Technologies). The DNA-lipid 
complexes were added to the cells and incubated overnight. The day after, cells were 
rinsed with PBS and new MEM was added. Transfected cells were used for 
experiments after 48 h. 
5.1.3 Imaging 
Experiments using NRVMs were carried out in HBSS at pH 7.4 (adjusted with 
NaOH) and at 37 °C.  
Images were acquired using an inverted fluorescence microscope (Leica 
DMI6000B equipped with DFC365FX camera) with PL APO 40x/1.25 oil objective. 
Fluorescence intensity was quantified using the Fiji distribution of the Java-based 
image processing program ImageJ (Schindelin et al., 2012), and background signal 
was subtracted from all analysed regions of interest. For Ca2+ imaging, traces were 
analysed using the “Peak Analyzer” tool of Origin Pro 9.1. 
To monitor mitochondrial ROS formation, cells were incubated with 25 nM 
MitoTracker Red CM-H2XRos (MTR, Thermo Fisher Scientific) for 30 min at 37°C in a 
humidified incubator. Since the accumulation of MTR in NRVMs can vary from different 
preparation, data were normalized to DMSO control.  
To monitor mitochondrial membrane potential (ΔΨm), cells were incubated with 
25 nM tetramethylrhodamine (TMRM, Thermo Fisher Scientific) in presence of 1.6 µM 
cyclosporin H (CsH) for 30 min at 37°C in a humidified incubator. TMRM fluorescence 
intensity was monitored following addition of 4 µM oligomycin (Sigma) and images 
were acquired before and after the addition of 4 µM carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP, Sigma) (Kaludercic et al., 2014). In order to 
have a reliable value of TMRM, fluorescence values were expressed as ΔF (F0/FFCCP) 
and results were normalized to DMSO control basal value. 
To monitor mPTP opening, cells were incubated with 1 µM calcein acetoxymethyl 
(AM) ester (Thermo Fisher Scientific) in presence of 1 mM Cobalt Chloride (CoCl2) for 
15 min at 37°C in a humidified incubator as previously described (Petronilli et al., 
1999). To evaluate the extent of pore opening, data were normalized to the basal 
value. 
To monitor [Ca2+]I homeostasis, cells were incubated with 5 µM Fluo-4 AM ester 
(Thermo Fisher Scientific), 0.01% w/v pluronic F-127 (Sigma) and 250 µM 
sulfinpyrazone (Sigma), for 20 min at 37°C in MEM followed by 20 min of de-
esterification. Since the accumulation of Fluo-4 in NRVMs can vary from different 
preparation, data were normalized to DMSO control. 
5.1.4 Assessment of cell death  
For normoxic experiments, NRVMs were seeded in 24w plates at density of 105 
cells/well and cultured in MEM supplemented with 1% FBS, 1% penicillin/streptomycin 
and 1% non-essential amino acids. Cells were incubated with different concentrations 
of MitoPQ with or without MPG or CsA for 24 h at 37°C in a humidified incubator 
For anoxia/reperfusion experiments, NRVMs were seeded in 24w plates at 
density of 105 cells/well and incubated in 118 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 
1.2 mM MgSO4, 2 mM CaCl2, 25 mM MOPS at pH 6.4 during anoxia or pH 7.4 during 
reoxygenation (Bond et al., 1991). Anoxia was induced adding 10 mM 2-deoxy-D-
glucose (2-DG) and incubating in a BD GasPak™ EZ Anaerobe Gas-generating 
Pouch System with an indicator (BD Biosciences) at 37°C for 12 h (Matsuoka et al., 
2002). To induce reoxygenation, plates were removed from the GasPak™ pouch, 2-
DG was replaced with 10 mM D-glucose, the pH was restored at 7.4. The plates were 
then incubated for 1 h in a humidified incubator at 37°C. 
The release of LDH from NRVMs was measured to evaluate cell death occurring 
in normoxia, anoxia and reoxygenation as described before (Bergmeyer and Bernt, 
1974; Di Lisa et al., 2001). Supernatant aliquots were collected after 24 h of normoxia, 
12 h of anoxia and 1 h of reoxygenation. At the end of every experiment, intact cells 
were lysed by incubating with 1% Triton X-100 (Sigma) for 30 min and supernatants 
were collected to evaluate the total amount of LDH. LDH enzymatic activity was 
measured spectrophotometrically by the absorbance of nicotinamide adenine 
dinucleotide (Roche) at 340 nm, indicative of the reduction of pyruvate to lactate. 
5.2 Experimental Animals 
Male C57BL/6J mice aged 8-10 weeks (22-32 g) were obtained from Charles 
River, UK. They were housed under standard laboratory conditions, with food and 
water available ad libitum. All procedures were carried out in accordance with the UK 
Home Office Guide on the Operation of Animal (Scientific Procedures) Act 1986 and 
University of Cambridge Animal Welfare Policy under project licenses 70/8238 and 
70/7963. 
5.3 Open-chest mouse model of acute myocardial I/R Injury 
An open chest model of acute myocardial ischaemia/reperfusion injury was used 
as described elsewhere (Eckle et al., 2006). Mice were anesthetized with sodium 
pentobarbital (70 mg/kg intraperitoneal), with depth of anaesthesia monitored via the 
pedal reflex and additional anaesthesia administered as required. Following left side 
lateral thoracotomy, the left anterior descending coronary artery was occluded for 30 
min followed by 2 h of reperfusion. Compounds were administered 15 min prior to the 
start of ischaemia by an intravenous bolus injection in the lateral tail vein. 
At the end of the protocol, the area at risk was delineated by retrograde injection 
of 10 mg/ml Evans Blue after re-occlusion of the left anterior descending coronary 
artery. Heart sections were incubated for 25 min at 37°C in 1% triphenyltetrazolium 
chloride (Sigma, UK) before fixing for 24 h in 10% formalin. Planimetry was performed 
in a blinded fashion using ImageJ (Schneider et al., 2012). Hearts in which the area at 
risk was outside of the range 30% - 60% of total area were excluded from any further 
analysis. 
5.4 Pressure-Volume analysis of cardiac function 
Anaesthesia was induced with 3% isoflurane in O2 in a plexiglass chamber. Mice 
were transferred to a heated surgical platform, and sufficient isoflurane administered 
to maintain a surgical plane of anaesthesia as assessed by the pedal reflex. Body 
temperature was maintained at 37°C using a rectal thermometer and temperature 
controller (TCAT-2LV, Physitemp, USA). The left ventricle was catheterized via the 
right carotid artery with a 1.2 French tetrapolar catheter (Transonic Scisense Inc, 
Canada) as described elsewhere (Pacher et al., 2008). In brief, a small midline incision 
was made in the neck in order to expose the carotid artery and isolate it from the vagus 
nerve. A 4-0 silk suture was tied tightly around the distal end of the artery, and two 
more sutures were placed loosely at the proximal end. Using a vascular clamp (0.4-1 
mm) to minimize blood loss, a small incision was made in the carotid artery with 
microscissors and the catheter inserted and secured using the additional sutures. The 
catheter was the inserted along the carotid until it was located centrally within the left 
ventricle, as indicated by the phase signal and by the shape of the resultant pressure-
magnitude loops. At least 15 min were allowed for the haemodynamics to stabilize. A 
100 µL bolus containing either 0.1 nmol MitoPQ or vehicle only was then injected via 
the lateral tail vein. Data were recorded at 1000 Hz using the ADV500 PV system 
(Transonic Scisense Inc, Canada) and a multi-channel acquisition system (Powerlab, 
ADInstruments, UK) and were analysed in LabChart (ADInstruments, UK). Volumes 
were calculated on dynamic basis using Wei’s equation (Larson et al., 2013). Three 
short sections of loops (within one breathing cycle) were examined at both baseline 
conditions and >5 minutes following injection. Upon completion of the protocol all 
animals were killed via cervical dislocation. 
5.5 Chemical synthesis 
MitoPQ was synthesized from iododecyl-TPP salt 1, which was prepared as 
described previously (Robb et al.) (Supplementary FIGURE 3). This was reacted with 
an excess of dimethyl-4,4’-dipyridyl 2, prepared by the procedure of (Rebek et al.), to 
minimise dialkylation. The monoalkylated product 3 was isolated in excellent year and 
was then methylated to give complete conversion to MitoPQ control. 
5.5.1 3-Methyl-4-(3”-methylpyrid-4”-yl)-1-(10”’-triphenylphosphoniodec-
1”’-yl)pyridinium diiodide 3 
(10-Iododec-1-yl)triphenylphosphonium iodide 1 (107 mg, 0.163 mmol, 1.0 eq.) 
was added to a solution of 3,3’-Dimethyl-4,4’-dipyridyl 2 (120 mg, 0.65 mmol, 4.0 eq) 
in MeCN (2 ml) and the resulting solution was heated to 60°C overnight under an 
atmosphere of argon. The solution was cooled to RT and concentrated under vacuum. 
Column chromatography eluting with CH2Cl2-MeOH (100:0 to 85:15) then gave the 
pyridinium salt 3 as an off-white solid (116 mg, 85%). nmax (ATR): 2926 (CH), 2854 
(CH), 1635 (Ar), 1437 (CH) cm–1. dH (400 MHz, CDCl3): 9.98 (1H, s, H-1), 9.71 (1H, d, 
J = 6.3 Hz, H-2), 8.62 (1H, s, H-4), 8.58 (1H, d, J = 5.0 Hz, H-5), 7.86-7.68 (16H, m, 
PPh3 + H-3), 7.06 (1H, d, J = 4.9 Hz, H-6), 4.97 (2H, t, J = 7.8 Hz, NCH2), 3.61-3.51 
(2H, m, PCH2), 2.37 (3H, s, CH3), 2.32 – 2.16 (2H, m, NCH2CH2), 2.10 (3H, s, CH3), 
1.70-1.60 (8H, m, 4 × CH2), 1.59-1.50 (2H, m, CH2), 1.49-1.25 (4H, m, 2 × CH2). dC 
(101 MHz, CDCl3): 154.85 (C), 151.42 (CH), 147.46 (CH), 145.16 (CH), 142.50 (CH), 
137.03 (C), 134.94 (d, J = 3.0 Hz, CH), 133.25 (d, J = 10.0 Hz, CH), 130.32 (d, J = 
12.6 Hz, CH), 129.32 (C), 127.45 (CH), 121.39 (CH), 117.60 (d, J = 86.0 Hz, C), 60.75 
(CH2), 31.17 (CH2), 29.81 (d, J = 15.8 Hz, CH2), 28.26 (CH2) , 28.17 (CH2), 27.99 
(CH2), 27.96 (CH2), 25.41 (CH2), 22.70 (d, J = 50.4 Hz, CH2), 22.11 (d, J = 4.4 Hz, 
CH2), 16.81 (CH3), 16.48 (CH3). dP (162 MHz: CDCl3): 23.94 (s). m/z (ESI): Found: 
293.1734. C40H47N2P requires (M2+), 293.1733.  
5.5.2 1,3,3’-trimethyl-1’-(10”’-triphenylphosphoniodec-1”’-yl)-4,4’-
bipyridinium (MitoPQ control) triiodide  
Iodomethane (19 µL, 0.29 mmol, 5.0 eq.) was added to a solution of pyridine 3 
(49 mg, 0.058mmol, 1.0 eq) in MeCN (1 ml) and the resulting solution was heated to 
40°C overnight under an atmosphere of argon. The solution was cooled to RT and 
concentrated under vacuum to give the MitoPQ triiodide as an off-white solid (57 mg, 
100%). nmax (ATR): 3016 (CH), 2926 (CH), 2854 (CH), 1635 (Ar), 1437 (CH) cm–1. dH 
(400 MHz, d3-MeCN): 9.14 (1H, s, H-1), 8.94 (1H, s, H-4), 8.91 (1H, d, J = 6.3 Hz, H-
2), 8.77 (1H, d, J = 6.3 Hz, H-5), 7.99 – 7.86 (5H, m, H-3, H-6 + 3 × ArH), 7.81 – 7.71 
(12H, m, 12 × ArH), 4.67 (2H, t, J = 7.6 Hz, NCH2), 4.42 (3H, s, NCH3), 3.35-3.23 (2H, 
m, PCH2), 2.30 (3H, s, CH3), 2.29 (3H, s, CH3), 2.07 (2H, q, J = 7.3 Hz, NCH2CH2), 
1.70-1.60 (2H, m, PCH2CH2), 1.58-1.49 (2H, m, CH2), 1.47-1.25 (10H, m, 5 × CH2). dC 
(101 MHz, d3-MeCN): 152.15 (C), 147.69 (CH), 146.81 (CH), 143.92 (CH), 143.12 
(CH), 138.41 (C), 137.98 (C), 135.86 (d, J = 3.0 Hz, CH), 134.55 (d, J = 10.0 Hz, CH), 
130.07 (d, J = 12.5 Hz, CH), 128.04 (CH), 127.81 (CH), 119.31 (d, J = 86.2 Hz, C), 
62.20 (CH2), 49.19 (CH3), 31.74 (CH2), 30.76 (d, J = 16.2 Hz, CH2), 29.55 (CH2), 29.48 
(CH2), 29.30 (CH2), 29.04 (CH2), 26.35 (CH2), 22.81 (d, J = 4.4 Hz, CH2), 22.61 (d, J 
= 50.7 Hz, CH2), 17.54 (CH3), 17.41 (CH3). dP (162 MHz: d3-MeCN): 23.84 (s). m/z 
(ESI): Found: 200.4568. C41H50N2P requires (M3+), 200.4565. 
5.6 Data analysis 
All values are expressed as mean ± S.E.M. Every set of data has 3 biological 
replicates (i.e. 3 different cardiac preparations) and every biological replicate has at 
least 3 technical replicates (i.e. 3 different samples of the same preparation). The 
propagation of error analysis was performed to take into account the uncertainty that 
is present in the experimental measurements due to measurement limitations (i.e. 
different accumulation of the sensor in NRVMs derived from different preparations). 
Comparison between groups was performed by one-way ANOVA, followed by post 
hoc testing (i.e. Tukey’s range test, Dunnett’s test) adjusted for multiple comparisons 
where data were normally distributed. Data that did not follow the normal distribution 
were statistically analysed by Kolgomorov-Smirnov’s test. Comparison between two 
groups was performed using a two-tailed Student’s t-test, with correction for multiple 
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7 Abbreviations 
[Ca2+]I – intracellular calcium concentration 
A/R – anoxia/reoxygenation 
CsA - cyclosporine A 
IPC – ischaemic preconditioning 
I/R – ischaemia/reperfusion 
LDH – lactate dehydrogenase 
MitoPQ – MitoParaquat 
MPG - N-(2-Mercaptopropionyl)glycine 
mPTP – Mitochondrial permeability transition pore 
MTR – mitotracker red CMH2X-ROS 
NRVM – neonatal rat ventricular myocytes 
TMRM - tetramethylrhodamine 
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because	the	coplanarity	required	for	a	delocalized	radical	cation	 is	disfavoured.	 	Thus,	complex	I	 is	not	sufficiently	
reducing	to	reduce	MitoPQ	control.	C)	Superoxide	production.	Bovine	heart	mitochondrial	membranes	(70	µg	protein)	
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